MEDXF (Medexus Pharmaceuticals) Total Equity: $48.99 Mil (As of Mar. 2026)


MEDXF Medexus Pharmaceuticals Inc MEDXF
60 GF Score
Price $3.62
GF Value $1.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Total Equity?

Medexus Pharmaceuticals MEDXF +3.96% 60 Total Equity is $48.99 Mil as of Mar. 2026. GuruFocus rates MEDXF with a GF Score™ of 60/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Medexus Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $48.99 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Medexus Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Total Equity Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.79 22.45 30.32 52.14 48.99

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.14 52.96 52.42 52.21 48.99
MEDXF
60GF Score
Medexus Pharmaceuticals Inc MEDXF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Medexus Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=147.284-98.294
=48.99

Medexus Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=147.284-98.294
=48.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $48.99 Mil mean?
Medexus Pharmaceuticals (MEDXF) has a Total Equity of $48.99 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Total Equity too high?
Medexus Pharmaceuticals' current Total Equity is $48.99 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Total Equity compare to ZTS and UTHR?
Medexus Pharmaceuticals' Total Equity of $48.99 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Total Equity is $48.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current Total Equity is $48.99 Mil. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Total Equity is $48.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEDXF:

  • Total Equity: $48.99 Mil
  • GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges P731:GermanyMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score

Get the complete analysis for MEDXF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.62
Price
$1.32
GF Value